Home Cart Sign in  
Chemical Structure| 95809-78-2 Chemical Structure| 95809-78-2

Structure of Devimistat
CAS No.: 95809-78-2

Chemical Structure| 95809-78-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer.

Synonyms: CPI-613

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Devimistat

CAS No. :95809-78-2
Formula : C22H28O2S2
M.W : 388.59
SMILES Code : O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2
Synonyms :
CPI-613
MDL No. :MFCD22420826
InChI Key :ZYRLHJIMTROTBO-UHFFFAOYSA-N
Pubchem ID :24770514

Safety of Devimistat

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302+H312-H315-H318-H411
Precautionary Statements:P264-P270-P273-P280-P301+P312+P330-P302+P352+P312-P305+P351+P338+P310-P332+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Target
  • Dehydrogenase

In Vitro:

Cell Line
Concentration Treated Time Description References
HN6 100 μM 24 hours To evaluate the effect of CPI-613 on ATP production in HNSCC cells, results showed that CPI-613 reduced ATP production PMC8670127
HN31 100 μM 24 hours To evaluate the effect of CPI-613 on ATP production in HNSCC cells, results showed that CPI-613 reduced ATP production PMC8670127
KNS42 cells 100 μM 24 hours To evaluate the effect of CPI-613 on the transcriptome of KNS42 cells, the results showed that CPI-613 suppressed gene sets related to oxidative phosphorylation and respiratory chain complexes. PMC11141877
Sk-Mel-5 300 µM 24 hours To detect the effect of CPI613 on glycolysis levels, the results showed that CPI613 significantly increased glycolysis levels, glycolytic capacity, and glycolytic reserve. PMC10496672
Pa03C 50 µM 24 hours To evaluate the effect of Devimistat on pancreatic cancer cell metabolism, results showed that Devimistat significantly reduced the utilization of TCA cycle substrates. PMC8353735
Panc10.05 50 µM 24 hours To evaluate the effect of Devimistat on pancreatic cancer cell metabolism, results showed that Devimistat significantly reduced the utilization of TCA cycle substrates. PMC8353735
B16F10 300 µM 48 hours To detect the effect of CPI613 on PD-L1 mRNA expression, the results showed that CPI613 significantly upregulated PD-L1 mRNA expression. PMC10496672
MCF7 150 µM 48 hours To evaluate the effect of CPI-613 on breast cancer cells, the results showed that the combination of CPI-613 with FRI-1 significantly increased cell death. PMC8533268
MDA-MB-231 150 µM 48 hours To evaluate the effect of CPI-613 on breast cancer cells, the results showed that the combination of CPI-613 with FRI-1 significantly increased cell death. PMC8533268
UWB1.289 MUT 75 µM 7 days CPI-613 treatment decreased CD133+ and CD117+ cell frequency and reduced sphere-forming capacity. PMC6896080
OVCAR3 75 µM 7 days CPI-613 treatment decreased CD133+ and CD117+ cell frequency and reduced sphere-forming capacity. PMC6896080
PANC-1 cells 1, 10, 50 μM 72 hours To evaluate the cytotoxicity of CPI-613 on PANC-1 cells, results showed that CPI-613 exhibited cytotoxicity at different concentrations. PMC7372733
PaTu-8902 cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. PMC8509312
HeLa cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. PMC8509312
Hep G2 cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. PMC8509312
HDF cells 50 µM 72 hours CPI-613 selectively kills cells adapted to acidosis through inhibition of the Krebs cycle and induction of oxidative stress, even in the presence of lactate. PMC8509312

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice tongue tumor model intraperitoneal injection 25 mg/kg every 3 days for 2 weeks To evaluate the therapeutic effect of CPI-613 on the tongue tumor model, results showed that CPI-613 significantly inhibited tumor growth PMC8670127
Mice orthotopic pancreatic cancer model intravenous injection CPI-613 10 mg/kg, LY2109761 13.2 mg/kg every 5 days for a total of 6 injections To evaluate the antitumor efficacy of the nanopolyplexes in a pancreatic cancer mouse model, results showed that the p-PPCL nanopolyplex significantly inhibited tumor growth. PMC7372733
Nude mice GBM12 xenograft model intraperitoneal injection 50 mg/kg 3 times per week, continuous treatment To evaluate the tumor growth inhibitory effect of CPI-613 combined with ABT263 in the GBM12 xenograft model, the results showed that the combination treatment significantly inhibited tumor growth. PMC11141877
NOD/SCIDγ(-/-) mice Pancreatic cancer xenograft model Oral 50 mg/kg Twice daily for 15 or 20 days To evaluate the antitumor effect of Devimistat on pancreatic cancer xenograft models, results showed that Devimistat significantly reduced tumor volume and weight. PMC8353735
NOD/SCID mice OVCAR3 xenograft model intraperitoneal injection 12.5 mg/kg once weekly for 2 weeks CPI-613 treatment decreased CD133+ and CD117+ cell frequency and inhibited tumor growth. PMC6896080

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01034475 Advanced Hematologic Malignanc... More >>ies Less << PHASE1 COMPLETED 2025-08-14 Wake Forest University Health ... More >>Sciences, Winston-Salem, North Carolina, 27012, United States Less <<
NCT03793140 Lymphoma|Leukemia PHASE2 ACTIVE_NOT_RECRUITING 2025-12-25 City of Hope, Duarte, Californ... More >>ia, 91010, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States|University of Pennsylvania (Data Collection Only), Philadelphia, Pennsylvania, 19104, United States|Md Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01520805 Acute Myeloid Leukemia (AML)|M... More >>yelodysplastic Syndrome (MDS) Less << PHASE2 WITHDRAWN 2025-12-18 Cornerstone Pharmaceuticals, I... More >>nc, Cranbury, New Jersey, 08512, United States Less <<
NCT00741403 Advanced Cancer|Metastatic Can... More >>cer|Lymphoma|Solid Tumors|Advanced Malignancies Less << PHASE1 COMPLETED 2025-12-16 Pivotal Research Centers, Peor... More >>ia, Arizona, 85381, United States|Eastchester Center for Cancer Care, Bronx, New York, 10469, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, 75201, United States|British Columbia Cancer Agency, Vancouver, British Columbia, Canada Less <<
NCT01832857 Cancer PHASE2 TERMINATED 2025-12-16 Eastchester Center for Cancer ... More >>Care, Bronx, New York, 10469, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.87mL

2.57mL

1.29mL

25.73mL

5.15mL

2.57mL

References

[1]Zachar Z, Marecek J, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011 Nov;89(11):1137-48.

[2]Lee KC, Shorr R, et al. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism. Drug Metab Lett. 2011 Aug;5(3):163-82.

[3]Stuart SD, Schauble A, et al. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4.

[4]Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, Schauble A, Lem J, Piramzadian A, Karnik S, Lee K, Rodriguez R, Shorr R, Bingham PM. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011 Nov;89(11):1137-48. doi: 10.1007/s00109-011-0785-8. Epub 2011 Jul 19. PMID: 21769686.

[5]Lee KC, Shorr R, Rodriguez R, Maturo C, Boteju LW, Sheldon A. Formation and anti-tumor activity of uncommon in vitro and in vivo metabolites of CPI-613, a novel anti-tumor compound that selectively alters tumor energy metabolism. Drug Metab Lett. 2011 Aug;5(3):163-82. doi: 10.2174/187231211796904991. PMID: 21722089.

[6]Stuart SD, Schauble A, Gupta S, Kennedy AD, Keppler BR, Bingham PM, Zachar Z. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4. doi: 10.1186/2049-3002-2-4. PMID: 24612826; PMCID: PMC4108059.

 

Historical Records

Categories